First author [Ref.] | Variables included | |||||||||||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | |
Gandhi 9 | Yes | W | Yes | S | ||||||||||||||
Migliori 10 | Yes | Yes | Yes | Yes | W | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | I | ||||
Migliori 11 | Yes | Yes | Yes | Yes | W/L | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | I | |||
Kim 12 | Yes | Yes | L | Yes | Yes | Yes | Yes | Yes | I | Yes | Yes | |||||||
Mitnick 16 | Yes | Yes | Yes | Yes | L | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | I | Yes | ||
Chan 17 | L | Yes | ||||||||||||||||
Keshavjee 19 | Yes | Yes | Yes | L | Yes | Yes | Yes | Yes | Yes | Yes | Yes | I | Yes | Yes | ||||
Eker 18 | Yes | Yes | Yes | Yes | Yes | L | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | I | Yes | Yes |
Kwon 20 | Yes | Yes | L | Yes | Yes | Yes | Yes | I | Yes | |||||||||
Lai 21 | Yes | Yes | Yes | |||||||||||||||
Banerjee 22 | Yes | W | Yes | Yes | Yes | Yes | I | |||||||||||
Bonilla 23 | Yes | Yes | Yes | L | Yes | Yes | Yes | Yes | Yes | S/I | ||||||||
Kim 24 | Yes | Yes | Yes | Yes | W | Yes | Yes | Yes | Yes | Yes | I | Yes |
1: representative sample (multidrug-resistant (MDR)-tuberculosis (TB) coverage); 2: history of previous treatment (MDR- versus extensively drug-resistant (XDR)-TB); 3: number with previous treatment for >1 month (MDR versus XDR); 4: number of drugs used in treatment (MDR versus XDR); 5: linezolid; 6: standard definitions according to Laserson et al. 28 (L) and/or the WHO (W); 7: number of drugs to which strains were resistant (MDR versus XDR); 8: 100% supranational reference laboratory quality assurance drug susceptibility testing; 9: all XDR-defining drugs tested; 10: times to sputum smear and/or culture conversion; 11: treatment success (MDR versus XDR); 12: failure (MDR versus XDR); 13: death (MDR versus XDR); 14: follow-up; 15: prevalence of HIV; 16: standard (S) or individualised (I) treatment; 17: surgery reported; 18: adverse events reported.